Literature DB >> 15099310

The history of sclerosing foams.

Jan-Christoph G R Wollmann1.   

Abstract

BACKGROUND: The use of foamed sclerosants in phlebology is undergoing a renaissance. The use of foam sclerotherapy was relaunched only a few years ago. Despite this, the early developments, pioneer findings, and improvements, especially in foaming techniques, are not widely recognized.
OBJECTIVE: The objective of this study was to give an overview from the very beginnings of foam sclerotherapy until the most recent and progressive techniques, as described by Tessari or the double syringe system technique.
RESULTS: The publications found after a thorough research for literature about foam sclerotherapy allow us to examine what has been invented between Orbach's work in 1944 and now and--surprisingly--even before 1944. The contributions of greatly reputed and also of unknown colleagues, such as Orbach, Sigg, Mayer, or Flückiger, are presented, giving a historical overview from the very beginnings of foam sclerotherapy until the most recent techniques. Basically, the literature shows that remarkable work was carried out in the field of noncommercial foam sclerotherapy and that sclerosing foams have been used by numerous doctors continuously for the past six decades, especially for the treatment of varicose veins of the lower limbs.
CONCLUSION: The use of foamed sclerosing agents in therapy of large or small varicose veins is not new. It started as early as 1939 and has continuously been improved in the past decades.

Mesh:

Substances:

Year:  2004        PMID: 15099310     DOI: 10.1111/j.1524-4725.2004.30208.x

Source DB:  PubMed          Journal:  Dermatol Surg        ISSN: 1076-0512            Impact factor:   3.398


  15 in total

Review 1.  [Sclerotherapy for varicosities].

Authors:  F Pannier; E Rabe
Journal:  Hautarzt       Date:  2006-01       Impact factor: 0.751

Review 2.  Matrix metalloproteinases as potential targets in the venous dilation associated with varicose veins.

Authors:  Arda Kucukguven; Raouf A Khalil
Journal:  Curr Drug Targets       Date:  2013-03       Impact factor: 3.465

3.  Optimal and safe treatment of spider leg veins measuring less than 1.5 mm on skin type IV patients, using repeated low-fluence Nd:YAG laser pulses after polidocanol injection.

Authors:  Javier Moreno-Moraga; Esteban Hernández; Josefina Royo; Justo Alcolea; M Jose Isarría; Mihail Lucian Pascu; Adriana Smarandache; Mario Trelles
Journal:  Lasers Med Sci       Date:  2012-08-11       Impact factor: 3.161

4.  Compression sclerotherapy for primary valvular insufficiency -from liquid to foam-.

Authors:  Takashi Yamaki
Journal:  Ann Vasc Dis       Date:  2010-07-21

Review 5.  [Guidelines for sclerotherapy of varicose veins : S2k guideline of the German Society of Phlebology (DGP) in cooperation with the following professional associations: DDG, DGA, DDG, BVP. German Version].

Authors:  E Rabe; F X Breu; I Flessenkämper; H Gerlach; S Guggenbichler; B Kahle; R Murena; S Reich-Schupke; T Schwarz; M Stücker; E Valesky; S Werth; F Pannier
Journal:  Hautarzt       Date:  2021-01       Impact factor: 0.751

6.  Left spermatic vein retrograde sclerosis: comparison between sclerosant agent injection through a diagnostic catheter versus through an occluding balloon catheter.

Authors:  Antonio Basile; Giovanni Failla; Sandro La Vignera; Rosita Angela Condorelli; Aldo Calogero; Enzo Vicari; Antonio Granata; Elena Mundo; Giuseppe Caltabiano; Marco Pizzarelli; Martina Messina; Giovanni Scavone; Franz Lanzafame; Roberto Iezzi; Dimitrios Tsetis
Journal:  Radiol Med       Date:  2014-12-02       Impact factor: 3.469

7.  Efficacy and safety of sclerotherapy with polidocanol foam in comparison with fluid sclerosant in the treatment of first-grade haemorrhoidal disease: a randomised, controlled, single-blind, multicentre trial.

Authors:  Karl-Heinz Moser; Christoph Mosch; Maren Walgenbach; Dieter G Bussen; Jan Kirsch; Andreas K Joos; Petra Gliem; Stefan Sauerland
Journal:  Int J Colorectal Dis       Date:  2013-06-18       Impact factor: 2.571

8.  Preparation, characterization and in vitro thrombolytic activity of a novel streptokinase foam.

Authors:  Abdo N Farret; Eduardo P Azevedo; Fernanda N Raffin
Journal:  J Thromb Thrombolysis       Date:  2014       Impact factor: 2.300

Review 9.  Polidocanol for endovenous microfoam sclerosant therapy.

Authors:  David M Eckmann
Journal:  Expert Opin Investig Drugs       Date:  2009-12       Impact factor: 6.206

10.  The role of clinically-relevant parameters on the cohesiveness of sclerosing foams in a biomimetic vein model.

Authors:  Dario Carugo; Dyan N Ankrett; Vincent O'Byrne; David D I Wright; Andrew L Lewis; Martyn Hill; Xunli Zhang
Journal:  J Mater Sci Mater Med       Date:  2015-10-08       Impact factor: 3.896

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.